


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claims 1-73 (cancelled)

Claim 74 (currently amended): A peptidomimetic of ~~claim 73~~ having the formula:




wherein

~~X₁ is (CH₂)_m or X₃;~~


~~X₂ bearing the R₅ substituent is independently CH₂ or N and all other X₂ are CH₂;~~

~~X₃ is C=O;~~

R₅ is



R₆ is -(CH₂)₄NH₂, -(CH₂)₃NHC(NH₂)=NH, -(CH₂)₃NHCOCH₃, -(CH₂)₃NHCOOCH₃,
 -(CH₂)₂NHC(NH₂)=NH, -(CH₂)₂NHCONH₂, -(CH₂)₄NHCOH, -(CH₂)₄NHCOCH₃,
 -(CH₂)₃NHCONHCH₃, -(CH₂)₃NHSO₂NH₂, -(CH₂)₃NHSO₂CH₃, -(CH₂)₃NH₂,
 -(CH₂)₂CONH₂, -(CH₂)₃NH(C=NH)NHMe, -(CH₂)₃NH(C=NH)NEt,
 -(CH₂)₃NH(C=NH)NHPr, -(CH₂)₃NH(C=NH)NHPr-i, -(CH₂)₃NH(C=NH)NH₂,
 -(CH₂)₄NHCONH₂, -(CH₂)₄NH(C=NH)NH₂,



R₇ is R₉–R₈–, where

R₈ is an L- or D-configuration of Phe, Phe(2-Cl), Phe(4-Cl), Phe(2,4-diCl), Phe(3,4-diCl), Phe(4-NO₂), Phe(4-Me), Phe(4-Phenyl), H₂Phe, Pgl, Trp, Nal 1, Nal 2, Bip, Dip, Bpa, Ser(Bzl), Lys(Z), Lys(Z-2'Br), Lys(Bz), Thr(Bzl), Cys(Bzl), Tyr(BzlCl₂), pF-Phe, Phe(4-Br), Phe(4-CF₃), Phe(3,4-diF), Phe(4-I) or Phe(3,4-di-OMe); and

R₉ is optionally not present or is an L- or D-configuration of His, Ser(Bzl), Tic, heptanoyl-Ser(Bzl), hexanoyl-Ser(Bzl), Hyp(Bzl), 4-phenylPro, 5-phenylPro, Tiq, Atc, Igl, Hyp(O-2-Naphthyl), Hyp(O-Phenyl), 2-Aic, Idc, 1-Aic, NH₂(CH₂)₆CO-, Benzyl, Beta-homoSer(Bzl), Ser(O-2-Naphthyl), Ser(O-Phenyl), Ser(O-4-Cl-Phenyl),

Ser(O-2-Cl-Phenyl), Thr(Bzl), Tic, heptanoyl-Thr(Bzl), hexanoyl-Thr(Bzl),
Beta-homoThr(Bzl), Thr(O-2-Naphthyl), Thr(O-Phenyl), Thr(O-4-Cl-Phenyl) or
Thr(O-2-Cl-Phenyl); and

n is 1; and

m is 1.

Claims 75-77 (cancelled)

Claim 78 (currently amended): A pharmaceutical composition comprising a
peptidomimetic of claim 74 ~~any one of claims 73-77~~ and a pharmaceutically acceptable carrier.

Claim 79 (currently amended): A method of treating a disease or condition comprising
administering a peptidomimetic of claim 74 ~~any one of claims 73-77~~, wherein the disease or
condition is an eating disorder, pathologic obesity, or sexual dysfunction.

Claim 80 (previously presented): The method of claim 79, wherein the sexual
dysfunction is male erectile dysfunction or female sexual dysfunction.

Claim 81 (previously presented): The method of claim 79, wherein the peptidomimetic is
administered as a pharmaceutical composition together with a pharmaceutically acceptable
carrier.